A Novel Type I IFN-Producing Cell Subset in Murine Lupus1

Excess type I IFNs (IFN-I) have been linked to the pathogenesis of systemic lupus erythematosus (SLE). Therapeutic use of IFN-I can trigger the onset of SLE and most lupus patients display up-regulation of a group of IFN-stimulated genes (ISGs). Although this “IFN signature” has been linked with disease activity, kidney involvement, and autoantibody production, the source of IFN-I production in SLE remains unclear. 2,6,10,14-Tetramethylpentadecane-induced lupus is at present the only model of SLE associated with excess IFN-I production and ISG expression. In this study, we demonstrate that tetramethylpentadecane treatment induces an accumulation of immature Ly6Chigh monocytes, which are a major source of IFN-I in this lupus model. Importantly, they were distinct from IFN-producing dendritic cells (DCs). The expression of IFN-I and ISGs was rapidly abolished by monocyte depletion whereas systemic ablation of DCs had little effect. In addition, there was a striking correlation between the numbers of Ly6Chigh monocytes and the production of lupus autoantibodies. Therefore, immature monocytes rather than DCs appear to be the primary source of IFN-I in this model of IFN-I-dependent lupus.

[1]  Kindra M Kelly-Scumpia,et al.  Deficiency of the type I interferon receptor protects mice from experimental lupus. , 2007, Arthritis and rheumatism.

[2]  F. Tacke,et al.  Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. , 2007, The Journal of clinical investigation.

[3]  Sadik H. Kassim,et al.  In Vivo Ablation of CD11c-Positive Dendritic Cells Increases Susceptibility to Herpes Simplex Virus Type 1 Infection and Diminishes NK and T-Cell Responses , 2006, Journal of Virology.

[4]  Y. Kuroda,et al.  Type I interferon production by tertiary lymphoid tissue developing in response to 2,6,10,14-tetramethyl-pentadecane (pristane). , 2006, The American journal of pathology.

[5]  E. Pamer,et al.  Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2 , 2006, Nature Immunology.

[6]  L. Rönnblom,et al.  The type I interferon system in systemic lupus erythematosus. , 2006, Arthritis and rheumatism.

[7]  D. Nacionales,et al.  Association of anti-nucleoprotein autoantibodies with upregulation of Type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosus. , 2005, Clinical immunology.

[8]  L. Moldawer,et al.  CD11c+ Dendritic Cells Are Required for Survival in Murine Polymicrobial Sepsis1 , 2005, The Journal of Immunology.

[9]  M. Peterson,et al.  Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. , 2005, Arthritis and rheumatism.

[10]  N. Van Rooijen,et al.  Subpopulations of Mouse Blood Monocytes Differ in Maturation Stage and Inflammatory Response1 , 2004, The Journal of Immunology.

[11]  Y. Kuroda,et al.  Distinctive patterns of autoimmune response induced by different types of mineral oil. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[12]  E. Coccia,et al.  Viral infection and Toll‐like receptor agonists induce a differential expression of type I and λ interferons in human plasmacytoid and monocyte‐derived dendritic cells , 2004, European journal of immunology.

[13]  G. Trinchieri,et al.  Mouse Strain Differences in Plasmacytoid Dendritic Cell Frequency and Function Revealed by a Novel Monoclonal Antibody , 2003, The Journal of Immunology.

[14]  J. Hamilton,et al.  The Phenotype of Inflammatory Macrophages Is Stimulus Dependent: Implications for the Nature of the Inflammatory Response1 , 2003, The Journal of Immunology.

[15]  B. Croker,et al.  Nephritogenic autoantibodies but absence of nephritis in Il-12p35-deficient mice with pristane-induced lupus. , 2003, Kidney international.

[16]  Steffen Jung,et al.  Blood monocytes consist of two principal subsets with distinct migratory properties. , 2003, Immunity.

[17]  Virginia Pascual,et al.  Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood , 2003, The Journal of experimental medicine.

[18]  G. Karypis,et al.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Steffen Jung,et al.  In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. , 2002, Immunity.

[20]  Marc Dalod,et al.  Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology , 2001, Nature Immunology.

[21]  Virginia Pascual,et al.  Induction of Dendritic Cell Differentiation by IFN-α in Systemic Lupus Erythematosus , 2001, Science.

[22]  F. Lund-Johansen,et al.  Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. , 2001, The American journal of pathology.

[23]  J. Smolen,et al.  Alterations of dendritic cells in systemic lupus erythematosus: phenotypic and functional deficiencies. , 2001, Arthritis and rheumatism.

[24]  F. Belardelli,et al.  Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. , 2001, Immunity.

[25]  N. Kadowaki,et al.  Natural Interferon α/β–Producing Cells Link Innate and Adaptive Immunity , 2000, The Journal of experimental medicine.

[26]  D. Jarrossay,et al.  Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon , 1999, Nature Medicine.

[27]  P. Marrack,et al.  Type I Interferons Keep Activated T Cells Alive , 1999, The Journal of experimental medicine.

[28]  M. Satoh,et al.  Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane , 1994, The Journal of experimental medicine.

[29]  N. Van Rooijen,et al.  Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. , 1994, Journal of immunological methods.

[30]  C. Snapper,et al.  Regulation by interferon alpha of immunoglobulin isotype selection and lymphokine production in mice , 1991, The Journal of experimental medicine.

[31]  L. Rönnblom,et al.  Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. , 1991, Annals of internal medicine.

[32]  I. Weissman,et al.  The stem cell antigens Sca-1 and Sca-2 subdivide thymic and peripheral T lymphocytes into unique subsets. , 1988, Journal of immunology.

[33]  A. Notkins,et al.  Immune interferon in the circulation of patients with autoimmune disease. , 1979, The New England journal of medicine.

[34]  J. Hollander.  ARTHRITIS AND ALLIED CONDITIONS , 1949 .

[35]  R. Schreiber,et al.  Bone Marrow Stromal Cell Antigen 2 Is a Specific Marker of Type I IFN-Producing Cells in the Naive Mouse, but a Promiscuous Cell Surface Antigen following IFN Stimulation , 2006 .

[36]  A. Cabral,et al.  Autoantibodies in systemic lupus erythematosus. , 1998, Current opinion in rheumatology.

[37]  F. Dumont,et al.  Interferon‐α/β enhances the expression of Ly‐6 antigens on T cells in vivo and in vitro , 1986 .

[38]  H. Yoshida,et al.  Interferon- (cid:1) is required for lupus nephritis in mice treated with the hydrocarbon oil pristane , 2022 .